Is Sermorelin Legal in Michigan? How to Access It Legally

What Sermorelin Is and Why It Requires a Prescription

Sermorelin acetate is a synthetic 29-amino-acid analog of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates the pulsatile secretion of endogenous growth hormone rather than introducing exogenous GH directly. That mechanism is why clinicians favor it over recombinant human growth hormone (rhGH) in many adult patients: the pituitary gland retains physiologic feedback control, which limits the risk of supraphysiologic GH spikes.

Because sermorelin acts on the pituitary-hypothalamic axis, prescribers treat it as a pharmaceutical agent requiring a valid prescription under Michigan law. Obtaining it without a prescription from an online vendor is not legal in Michigan or any other U.S. State.

Historical FDA Approval

The FDA approved Geref Diagnostic (sermorelin acetate for injection, Serono Laboratories) for stimulation testing of GH secretion in children. That product was voluntarily withdrawn from the U.S. Market by the manufacturer around 2002 for commercial reasons, not safety concerns. The withdrawal does not make sermorelin illegal. It means no finished-dosage product is currently sold under an approved New Drug Application (NDA), which shifts all legitimate access to the compounding pharmacy pathway. The FDA's own database confirms no currently approved NDA for sermorelin as a therapeutic agent, and the agency has not placed sermorelin on its "Difficult to Compound" or "Categories 1/2" lists that would prohibit 503B outsourcing-facility use.

Why Compounding Is the Legal Route

Under the Federal Food, Drug, and Cosmetic Act, Section 503A governs traditional compounding pharmacies that prepare patient-specific prescriptions. Section 503B governs outsourcing facilities that produce larger batches without patient-specific prescriptions. Both pathways require state pharmacy board licensure in addition to federal compliance. Michigan-licensed 503A pharmacies may legally dispense compounded sermorelin when a Michigan-licensed prescriber writes an order for a named patient. [1]

Federal Legal Framework: FDA Rules That Apply in Every State

Michigan residents are subject to the same federal rules as patients anywhere in the country. Understanding those rules is the first step to accessing sermorelin through a legitimate channel.

The FD&C Act Section 503A Pathway

Section 503A of the FD&C Act allows licensed pharmacists to compound drugs for individual patients when a valid prescription exists, the drug is not on the FDA's list of "Drugs Withdrawn or Removed from the Market for Safety Reasons," and the pharmacy does not compound "essentially a copy" of a commercially available product. Because no commercial sermorelin product is currently on the market, the "essentially a copy" restriction does not apply. [2]

503A pharmacies must use bulk drug substances that appear on an FDA-approved list (the "503A Bulks List") or are components of approved drugs. Sermorelin acetate has been used in compounding under long-standing pharmacy practice. Prescribers should verify that their chosen pharmacy sources pharmaceutical-grade sermorelin from an FDA-registered bulk manufacturer with a valid Certificate of Analysis.

The FD&C Act Section 503B Pathway

503B outsourcing facilities operate under current Good Manufacturing Practice (cGMP) standards and can ship product across state lines to prescribers' offices without patient-specific prescriptions. The FDA maintains a public list of registered 503B facilities. [3] Michigan-based clinics and telehealth providers may receive sermorelin vials from a registered 503B facility and dispense them to patients under a physician's supervision. This pathway offers tighter quality control because 503B facilities face more rigorous FDA inspection than 503A pharmacies.

The Research Chemical Gray Area

Some online vendors sell "sermorelin for research use only" without any prescription requirement. That label does not make the product legal for human use. The FDA considers any peptide sold with implicit or explicit claims for human administration to be an unapproved new drug. Purchasing such products exposes buyers to unknown purity, incorrect dosing, and potential federal enforcement. [4] No credible Michigan clinician or compounding pharmacy would source sermorelin from a "research chemical" supplier.

Michigan State Law: What the Michigan Board of Pharmacy and Medical Practice Act Require

Michigan Public Health Code and Prescription Requirements

Michigan's Public Health Code (Act 368 of 1978, MCL 333.1101 et seq.) defines the practice of medicine and the dispensing of prescription drugs within the state. Sermorelin, as a compounded prescription drug, falls under those provisions. A prescription must be written by a licensed Michigan physician (MD or DO), a licensed physician assistant under physician supervision, or a licensed nurse practitioner operating within their scope of practice. The prescription must include the patient's name, the drug name and strength, the quantity, directions for use, and the prescriber's signature and DEA number.

Michigan does not impose any additional controlled-substance scheduling on sermorelin beyond federal law. The DEA does not schedule it as a controlled substance, so no Schedule II triplicate form is required. [5]

Michigan Board of Pharmacy Oversight

The Michigan Board of Pharmacy licenses and inspects in-state compounding pharmacies. Any Michigan 503A pharmacy compounding sermorelin must hold an active state license and comply with USP Chapter 795 (non-sterile) and USP Chapter 797 (sterile preparations) standards. Because sermorelin is administered by subcutaneous injection, USP 797 governs its preparation, including sterility testing and beyond-use dating requirements. [6] Patients and prescribers can verify a pharmacy's active license on the Michigan Department of Licensing and Regulatory Affairs (LARA) website.

No Michigan-Specific Ban on Sermorelin

A review of Michigan statutes, the Michigan Board of Pharmacy's published guidance, and the Michigan Medical Practice Act reveals no state-level prohibition on prescribing or dispensing compounded sermorelin. No Michigan court ruling currently restricts it. State law in Michigan follows federal law on this point: the prescription drug framework governs access, and a valid prescription written by a licensed provider satisfies that framework.

The table below summarizes the compliance checklist a Michigan clinician should walk through before prescribing sermorelin.

| Step | Requirement | Governing Authority | |------|-------------|---------------------| | 1. Diagnosis documentation | Documented clinical signs of GH deficiency or age-related decline | Michigan Medical Practice Act | | 2. Lab baseline | IGF-1, fasting glucose, HbA1c, thyroid panel | Standard of care | | 3. Valid prescription | Named patient, dose, route, quantity, DEA number | Michigan Public Health Code | | 4. Pharmacy verification | Active Michigan Board of Pharmacy license, USP 797 compliance | Michigan Board of Pharmacy | | 5. Bulk substance verification | Pharmacy sources from FDA-registered bulk manufacturer | FDA FD&C Act 503A/503B | | 6. Follow-up monitoring | Repeat IGF-1 at 8 to 12 weeks | Endocrine Society guidelines |

Clinical Basis for Sermorelin Prescribing in Michigan Adults

Prescribers in Michigan order sermorelin primarily for adult patients with documented or suspected growth hormone deficiency (GHD), age-related GH decline (somatopause), body composition concerns, or sleep disruption associated with blunted nocturnal GH pulses.

Evidence on Growth Hormone Secretion

Sermorelin's mechanism has been characterized in peer-reviewed literature for decades. A key pharmacodynamic study published in the Journal of Clinical Endocrinology and Metabolism confirmed that 29-amino-acid GHRH analogs produce dose-dependent GH release from somatotrophs, with peak serum GH occurring 15 to 30 minutes after subcutaneous injection. [7] That physiologic pulsatility preserves the feedback loop through somatostatin, reducing the overshoot risk seen with exogenous rhGH.

IGF-1 as the Primary Monitoring Biomarker

The Endocrine Society's 2011 Clinical Practice Guideline on Adult GHD states: "We recommend using serum IGF-1 concentrations to guide GH dose titration, with a treatment target of maintaining IGF-1 in the mid-normal range for age and sex." [8] Michigan prescribers follow that standard when managing sermorelin therapy. IGF-1 drawn at baseline, then again at 8 to 12 weeks, allows dose adjustment before the patient completes the initial treatment course.

A study in the journal Aging (Albany, NY) reported that six months of GHRH analog therapy in adults aged 40 to 65 years produced a mean increase in lean mass of 1.5 kg and a mean reduction in trunk fat mass of 0.9 kg compared to placebo (P<0.05, N=82). [9] Body composition improvements were accompanied by self-reported improvements in sleep quality and energy in 63% of participants.

Typical Dosing Parameters

Most Michigan compounding pharmacies dispense sermorelin at concentrations of 2 mg/mL or 5 mg/mL in bacteriostatic water. Standard starting doses range from 200 mcg to 500 mcg administered subcutaneously at bedtime to align with the physiologic nocturnal GH surge. Prescribers titrate upward based on IGF-1 response and tolerability, not to exceed the range that keeps IGF-1 within the age-adjusted normal reference interval. Treatment courses typically run 3 to 6 months, followed by a lab reassessment and a decision on continuation.

How to Get Sermorelin in Michigan: Step-by-Step

Getting a legitimate sermorelin prescription in Michigan follows a defined process. Short-cuts that bypass any of these steps place the patient outside legal compliance.

Step 1. See a Qualified Michigan Prescriber

The patient needs an in-person or telehealth consultation with a Michigan-licensed physician, PA, or NP. The prescriber should hold relevant expertise in endocrinology, men's health, women's health, or anti-aging medicine. At the consultation, the prescriber takes a history, reviews symptoms consistent with GH deficiency or somatopause, and orders baseline labs. A Michigan-based telehealth practice may conduct the initial consultation via a synchronous video visit, which satisfies the Michigan Telehealth statute (MCL 333.16285) as long as a proper prescriber-patient relationship is established before any prescription is written.

Step 2. Complete Baseline Laboratory Work

Labs drawn before a sermorelin prescription is written typically include:

• Serum IGF-1 (age and sex-adjusted reference range)
• Fasting insulin-like growth factor binding protein-3 (IGFBP-3)
• Fasting glucose and HbA1c (sermorelin may transiently reduce insulin sensitivity)
• Comprehensive metabolic panel
• Thyroid-stimulating hormone (TSH) and free T4

Uncontrolled diabetes or active malignancy are contraindications to sermorelin therapy. The FDA package insert for the original Geref Diagnostic product listed glucose intolerance as a precaution requiring monitoring. [10]

Step 3. Receive and Fill the Prescription

The prescriber transmits the prescription electronically or by phone to a Michigan-licensed 503A compounding pharmacy or a registered 503B outsourcing facility. The patient should ask the pharmacy for the bulk substance Certificate of Analysis (COA) and confirm the pharmacy holds active Michigan Board of Pharmacy licensure. Pricing for a 30-day supply of compounded sermorelin typically runs $100, $200, varying by concentration and pharmacy.

Step 4. Proper Storage and Administration

Reconstituted sermorelin must be stored at 2 to 8 degrees Celsius (standard refrigerator temperature) and used within the beyond-use date stamped by the compounding pharmacy under USP 797 guidance. Patients self-administer subcutaneous injections using a 29- or 31-gauge insulin syringe, rotating injection sites between the abdomen and lateral thigh.

Step 5. Follow-Up Monitoring

At 8 to 12 weeks, the prescriber orders a repeat IGF-1. The Endocrine Society guideline recommends maintaining IGF-1 "in the mid-normal range for age and sex." [8] If IGF-1 remains below the lower limit of normal, the dose may be titrated upward by 100 to 200 mcg increments. If IGF-1 exceeds the upper limit of normal, the dose is reduced or the therapy is paused.

Sermorelin vs. Other GHRH Peptides: Legal Distinctions Michigan Patients Should Know

Michigan patients frequently ask about related peptides: CJC-1295, ipamorelin, tesamorelin, and MK-677 (ibutamoren). Each has a different regulatory status.

Tesamorelin

Tesamorelin (brand name Egrifta) is FDA-approved for HIV-associated lipodystrophy and is the only GHRH analog with a current active NDA. A Michigan prescriber may prescribe it on-label without any compounding. [11] Off-label use for other indications is legally permissible under physician judgment but is not covered by most insurers outside the approved indication.

CJC-1295 and Ipamorelin

CJC-1295 and ipamorelin are not FDA-approved for any indication. The FDA placed CJC-1295 on the list of bulk drug substances that may not be used in compounding under 503A and 503B (Category 2 substances). Michigan pharmacies may not legally compound CJC-1295. [12] Ipamorelin's regulatory status remains under FDA review. Michigan prescribers should confirm current FDA guidance before ordering any compounded ipamorelin.

MK-677 (Ibutamoren)

MK-677 is an oral GH secretagogue under clinical investigation. It is not FDA-approved, has not been granted IND status for general prescribing, and is not legally compoundable for human use. Products sold online as MK-677 occupy the same research-chemical gray zone described above. Michigan clinicians should not prescribe it outside an IRB-approved clinical trial.

Safety Profile and Contraindications

Common Adverse Effects

Sermorelin's adverse effect profile from the original Geref clinical data and post-market experience includes transient injection-site reactions (redness, swelling in roughly 17% of patients), flushing, headache, and dizziness. [10] These effects are typically mild and self-limiting. Facial flushing occurs more often when the injection is given rapidly; a slow 30-second push reduces incidence.

Serious Concerns

Patients with active or suspected intracranial neoplasm should not receive sermorelin, because GH stimulation could theoretically promote tumor growth. Patients with uncontrolled hypothyroidism may have a blunted response. The Endocrine Society guideline notes: "GH replacement is contraindicated in patients with active malignancy, intracranial hypertension, or proliferative or preproliferative diabetic retinopathy." [8] That contraindication applies to sermorelin as well by extension of mechanism.

Drug Interactions

Glucocorticoids suppress GH secretion and may blunt sermorelin's effect. Patients on chronic prednisone or hydrocortisone therapy may need higher doses or may not respond adequately. Conversely, estrogen supplementation at high doses can increase GH secretion; women on oral estrogen therapy may require sermorelin dose adjustments to keep IGF-1 within the normal range.

Telehealth Access to Sermorelin in Michigan

Michigan's telehealth statute allows licensed Michigan prescribers to evaluate patients via synchronous audio-video technology and issue prescriptions, including for compounded sermorelin, without a prior in-person visit as long as the standard of care for evaluation is met. The Michigan Department of Licensing and Regulatory Affairs has confirmed that telehealth prescribing of non-controlled substances is permissible when an appropriate prescriber-patient relationship exists. [13]

For patients outside major metropolitan areas (Detroit, Grand Rapids, Ann Arbor, Lansing), telehealth is the most practical access path. The prescriber still must be Michigan-licensed or hold a valid Michigan telehealth license. Prescriptions from out-of-state providers who are not licensed in Michigan are not legally valid for a Michigan patient.

Insurance Coverage and Cost Considerations

No commercial insurer currently covers compounded sermorelin for anti-aging or body composition purposes. Coverage for documented adult GHD is inconsistent even for approved rhGH products; compounded sermorelin faces additional barriers because it lacks an active NDA. Medicare Part D does not cover compounded drugs for Medicare beneficiaries. Patients should expect to pay out of pocket.

A 30-day supply at 300 mcg nightly (a 2 mg/mL vial, 1 mL daily) from a Michigan-licensed compounding pharmacy runs approximately $120, $180. Over a 3-month initial course, total medication cost is roughly $360, $540, plus the cost of laboratory monitoring and medical visits.